| pubmed-article:11149742 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11149742 | lifeskim:mentions | umls-concept:C0015020 | lld:lifeskim |
| pubmed-article:11149742 | lifeskim:mentions | umls-concept:C0439859 | lld:lifeskim |
| pubmed-article:11149742 | lifeskim:mentions | umls-concept:C0242602 | lld:lifeskim |
| pubmed-article:11149742 | lifeskim:mentions | umls-concept:C1328050 | lld:lifeskim |
| pubmed-article:11149742 | lifeskim:mentions | umls-concept:C1524063 | lld:lifeskim |
| pubmed-article:11149742 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:11149742 | pubmed:dateCreated | 2001-1-8 | lld:pubmed |
| pubmed-article:11149742 | pubmed:abstractText | This report describes two patients with germ cell tumors who underwent tandem autologous peripheral stem cell transplants. The chemotherapy consisted of high-dose carboplatin and etoposide. Both patients developed chemotherapy-related toxicities, which included nephrotoxicity in one case and febrile neutropenia, thrombocytopenia, ototoxicity and mucositis in both. During the second transplant, both patients received amifostine 15 min before and 2 h after each dose of carboplatin. The patients had less mucositis and nephrotoxicity. The duration of neutropenia and thrombocytopenia was less in both cases resulting in a decreased use of antibiotics and platelet transfusions. These cases suggest that the use of amifostine may be of benefit in minimizing toxicities associated with high-dose chemotherapy. | lld:pubmed |
| pubmed-article:11149742 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11149742 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11149742 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11149742 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11149742 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11149742 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11149742 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11149742 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11149742 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11149742 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:11149742 | pubmed:issn | 0268-3369 | lld:pubmed |
| pubmed-article:11149742 | pubmed:author | pubmed-author:Ratanatharath... | lld:pubmed |
| pubmed-article:11149742 | pubmed:author | pubmed-author:RaithCC | lld:pubmed |
| pubmed-article:11149742 | pubmed:author | pubmed-author:CroninSS | lld:pubmed |
| pubmed-article:11149742 | pubmed:author | pubmed-author:AyashL JLJ | lld:pubmed |
| pubmed-article:11149742 | pubmed:author | pubmed-author:UbertiJ PJP | lld:pubmed |
| pubmed-article:11149742 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11149742 | pubmed:volume | 26 | lld:pubmed |
| pubmed-article:11149742 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11149742 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11149742 | pubmed:pagination | 1247-9 | lld:pubmed |
| pubmed-article:11149742 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:11149742 | pubmed:meshHeading | pubmed-meshheading:11149742... | lld:pubmed |
| pubmed-article:11149742 | pubmed:meshHeading | pubmed-meshheading:11149742... | lld:pubmed |
| pubmed-article:11149742 | pubmed:meshHeading | pubmed-meshheading:11149742... | lld:pubmed |
| pubmed-article:11149742 | pubmed:meshHeading | pubmed-meshheading:11149742... | lld:pubmed |
| pubmed-article:11149742 | pubmed:meshHeading | pubmed-meshheading:11149742... | lld:pubmed |
| pubmed-article:11149742 | pubmed:meshHeading | pubmed-meshheading:11149742... | lld:pubmed |
| pubmed-article:11149742 | pubmed:meshHeading | pubmed-meshheading:11149742... | lld:pubmed |
| pubmed-article:11149742 | pubmed:meshHeading | pubmed-meshheading:11149742... | lld:pubmed |
| pubmed-article:11149742 | pubmed:meshHeading | pubmed-meshheading:11149742... | lld:pubmed |
| pubmed-article:11149742 | pubmed:meshHeading | pubmed-meshheading:11149742... | lld:pubmed |
| pubmed-article:11149742 | pubmed:meshHeading | pubmed-meshheading:11149742... | lld:pubmed |
| pubmed-article:11149742 | pubmed:meshHeading | pubmed-meshheading:11149742... | lld:pubmed |
| pubmed-article:11149742 | pubmed:meshHeading | pubmed-meshheading:11149742... | lld:pubmed |
| pubmed-article:11149742 | pubmed:meshHeading | pubmed-meshheading:11149742... | lld:pubmed |
| pubmed-article:11149742 | pubmed:meshHeading | pubmed-meshheading:11149742... | lld:pubmed |
| pubmed-article:11149742 | pubmed:meshHeading | pubmed-meshheading:11149742... | lld:pubmed |
| pubmed-article:11149742 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:11149742 | pubmed:articleTitle | Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem cell transplantation. | lld:pubmed |
| pubmed-article:11149742 | pubmed:affiliation | Blood and Marrow Stem Cell Transplantation Program, College of Pharmacy, University of Michigan Medical Center, Ann Arbor, USA. | lld:pubmed |
| pubmed-article:11149742 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11149742 | pubmed:publicationType | Case Reports | lld:pubmed |
